FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma
Evidence for efficacy is based on the results from the EPCORE NHL-1 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Significant PFS Benefit in Patients with HR-positive, HER2-negative MBC Who Switched Endocrine Treatment and Received Ribociclib After Previous CDK4/6 Inhibitor and Different Endocrine Therapy
Findings from the MAINTAIN study
Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients with Cancer and HIV Even in Those on Antiretroviral Therapy
Findings from the CATCH-IT Consortium study
Pralsetinib: Measures to Minimise Increased Risk for Tuberculosis
Before starting treatment with pralsetinib, patients should be evaluated for active and latent tuberculosis
Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients with HER2-positive Metastatic Breast Cancer
PRO data from the DESTINY-Breast03 study
ctDNA Sequencing Reliably Detects KIT/PDGFRA Mutations and Correlates with Outcomes in Patients with Metastatic, TKI-Resistant GIST Treated with Avapritinib or Regorafenib
Findings from the ctDNA analysis in the VOYAGER study
Venetoclax-Obinutuzumab With or Without Ibrutinib Is Superior to Chemoimmunotherapy in First-Line Treatment for Fit Patients with CLL
Findings from the GAIA–CLL13 study
Cabozantinib Plus Nivolumab and Ipilimumab Results in Longer PFS in Previously Untreated, Advanced RCC with Intermediate or Poor Prognostic Risk
Findings from the COSMIC-313 study
EMA Recommends Granting a Conditional Marketing Authorisation for Glofitamab
It is intended for the treatment of adult patients with relapsed or refractory DLBCL after two or more lines of systemic treatment
POT1 Mutations Associated with Long Telomere Length Confer a Predisposition to a Familial Clonal Haematopoiesis Syndrome
An inherited cancer-predisposition mechanism distinct from that of mutations affecting tumour-suppressor proteins and oncoproteins
Multi-Organ Genomic Analysis of Resistant Cutaneous Melanoma Provides Insights for Potential Improvement of Treatment Strategies
Findings from genomic analysis in a rapid autopsy cohort study
Long-Term Benefit of Sotorasib in Patients with Pretreated KRASG12C-Mutated NSCLC
Findings from 2-year analysis of CodeBreaK 100 study